Table I.
Sensitivity, specificity, positive predictive value and negative predictive value of T-cell receptor gamma (TCRG) and T-cell receptor beta (TCRB) BIOMED-2 Concerted Action BMH4-CT98-3936 (BIOMED-2) PCR in cases of cutaneous T-cell lymphomas (CTCLs) and early MF
| CTCLs (n = 104) vs BCLI (n = 130) | ||||
|---|---|---|---|---|
| TCRG% (95% CI) | TCRB% (95% CI) | TCRG + TCRB % (95% CI) | ||
| Sensitivity | 74.0 (64.5–82.1) | 78.8 (69.7–86.2) | 89.4 (81.9–94.6) | |
| Specificity | 87.7 (80.8–92.8) | 89.2 (82.6–94.0) | 81.5 (73.8–87.8) | |
| ppv | 82.8 (73.6–89.8) | 85.4 (76.7–91.8) | 79.5 (71.0–86.4) | |
| NPV | 80.9 (73.4–87.0) | 84.1 (76.9–89.7) | 90.6 (83.8–95.2) | |
|
| ||||
| TCRG vs TCRB | TCRG vs TCRG + TCRB | TCRB vs TCRG + TCRB | ||
| Sen. p = 0.442 | Sen. p < 0.001 | Sen. p = 0.001 | ||
| Spe. p = 0.815 | Spe. p = 0.008 | Spe. p = 0.002 | ||
| ppv p=0.501 | PPV p = 0.134 | PPV p = 0.013 | ||
| NPV p = 0.304 | NPV p < 0.001 | NPV p= 0.003 | ||
|
| ||||
| Early MF (n = 46) vs BCLI (n = 110)a | ||||
|
| ||||
| TCRG% (95% CI) | TCRB% (95% CI) | TCRG + TCRB % (95% CI) | ||
| Sensitivity | 69.6 (54.2–82.3) | 78.3 (63.6–89.1) | 89.1 (76.4–96.4) | |
| Specificity | 91.8 (85.0–96.2) | 90.9 (83.9–95.6) | 85.5 (77.5–91.5) | |
| ppv | 78.0 (62.4–89.4) | 78.3 (63.6–89.1) | 71.9 (58.5–83.0) | |
| NPV | 87.8 (80.4–93.2) | 90.9 (83.9–95.6) | 94.9 (88.6–98.3) | |
|
| ||||
| TCRG vs TCRB | TCRG vs TCRG + TCRB | TCRB vs TCRG + TCRB | ||
| Sen. p = 0.424 | Sen. p = 0.004 | Sen. p = 0.063 | ||
| Spe. p = 1.000 | Spe. p = 0.016 | Spe. p = 0.031 | ||
| PPV p = 0.975 | PPV p =0.136 | PPV p = 0.077 | ||
| NPV p = 0.302 | NPV p = 0.004 | NPV p =0.037 | ||
a
Benign cutaneous lymphoid infiltrates (BCLI) used as negative controls for the diagnosis of early mycosis fungoides (MF) did not include erythrodermic or tumoral clinical presentations.
CI: confidence interval; NPV: negative predictive value; PPV: positive predictive value; Sen: sensitivity; Spe: specificity.